Advertisement

Prediction of hypertensive disorders of pregnancy using metabolomics: there is a long way to go

Published:January 20, 2023DOI:https://doi.org/10.1016/j.ajogmf.2023.100865
      Hypertensive disorders of pregnancy (HDP) are the most common medical complication of pregnancy, affecting about 10% of pregnancies.1 They are still a leading cause of maternal and perinatal mortality worldwide. As a consequence, antenatal care is devoted in large part to their detection and prediction. Risk factors for HDP are related to clinical epidemiological, hemodynamic, and basic biochemical factors. For example, combining clinical maternal risk markers, placental growth factor and uterine artery pulsatility index in the first trimester has sensitivities of 75% for preterm preeclampsia and 47% for term preeclampsia, compared with sensitivities of 34% and 39%, respectively, for use of clinical risk markers alone.2
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology MFM
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect